LeMaitre Vascular, Inc.(LMAT)- NASDAQ
  • Aug. 18, 2014, 1:56 PM
    • LeMaitre Vascular (LMAT +3%) acquires Australian firm Xenotis, the manufacturer of the Omniflow II biological graft for peripheral bypass and dialysis access, for $7.7M (including the assumption of $1.2M in debt).
    • The Omniflow has been implanted over 20K times since 1990.
    | Aug. 18, 2014, 1:56 PM
  • Aug. 28, 2013, 1:19 PM
    • LeMaitre Vascular (LMAT +2.3%) says it's acquired the assets of InaVein for $2.5M.
    • The purchase price represents 1.1X of InaVein's 2012 sales, and potential earn-out payments in 2014 and 2015 based on the performance of the acquired business and regulatory approval in China.
    • InaVein owned and marketed the TRIVEX System, which carries an attractive 60% - 70% gross margin.
    | Aug. 28, 2013, 1:19 PM
  • Jul. 9, 2013, 4:23 PM

    LeMaitre Vascular (LMAT) acquires the assets of shunt and catheter maker Clinical Instruments International for $1.1M (catheters and shunts are LMAT's #2 and #3 products). The purchase price represents 1.7x Clinical Instruments' 2012 revenue. (PR)

    | Jul. 9, 2013, 4:23 PM
Company Description
LeMaitre Vascular, Inc. is a medical device company, which provides medical devices for the treatment of peripheral vascular disease. The company design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease. Its products line... More
Sector: Healthcare
Industry: Medical Instruments & Supplies
Country: United States